AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10638883 — intervention group
Group type: COMPARATOR
Intervention: Absence of the object (participants reached forward to the place where coins would be placed)
Number of subjects: 39
Study 8623790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 657
Study 1356459 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g and metronidazole 1 g before operation and fosfomycin 8 g eight hours afterwards
Number of subjects: 559
Study 1356459 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 400 mg and metronidazole 1 g before operation, and placebo eight hours afterwards
Number of subjects: 559
Study 3883878 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg
Number of subjects: 28
Study 3883878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31691886 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 0
Study 31691886 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study 29193234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-dexmedetomidine group (group RD, n = 19) received 15 mL of 0.5% ropivacaine with 100 μg (1 mL) dexmedetomidine
Number of subjects: 37
Study 29193234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-dexmedetomidine group (group RD, n = 19)
Number of subjects: 37
Study 29193234 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine group (group R, n = 18)
Number of subjects: 37
Study 28238618 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate re-feed post-simulation
Number of subjects: 15
Study 28238618 — intervention group
Group type: COMPARATOR
Intervention: Delayed re-feed (2-h post)
Number of subjects: 15
Study 28238618 — intervention group
Group type: EXPERIMENTAL
Intervention: All players (post-simulation)
Number of subjects: 15
Study 25326169 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.2 mg/kg intra-arterial bolus)
Number of subjects: 100
Study 25326169 — intervention group
Group type: COMPARATOR
Intervention: Heparin and/or aspirin (control group)
Number of subjects: 100
Study 24273969 — intervention group
Group type: EXPERIMENTAL
Intervention: DFSE + controlled ovarian hyperstimulation (COH)
Number of subjects: 70
Study 24273969 — intervention group
Group type: COMPARATOR
Intervention: DFSE placebo + controlled ovarian hyperstimulation (COH)
Number of subjects: 70
Study 21142353 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (video intervention)
Number of subjects: 138
Study 21142353 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral video)
Number of subjects: 138
Study 18772807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in late-stage AMD (n=12)
Number of subjects: 30
Study 18772807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in early-stage AMD (n=30)
Number of subjects: 30
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom questionnaires
Number of subjects: 2032
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple questionnaire concerning the preceding 2 weeks
Number of subjects: 2032
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data including asthma questionnaires
Number of subjects: 2032
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medications and peak flow measurements
Number of subjects: 2032
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids and unscheduled health care visits
Number of subjects: 2032
Study 17157651 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors (smoking, ethnicity, lung function, asthma history)
Number of subjects: 2032
Study 14567168 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 5 mg
Number of subjects: 28
Study 14567168 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 100 mg
Number of subjects: 28
Study 14567168 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study 11503260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten, 400 mg once daily
Number of subjects: 406
Study 11503260 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (b.i.d. dosing)
Number of subjects: 406
Study 11503260 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (t.i.d. dosing)
Number of subjects: 406
Study 11503260 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance for all groups
Number of subjects: 406
Study 11503260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing frequency
Number of subjects: 406
Study 9689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120
Study 9689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 120
Study 9689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 4 mg
Number of subjects: 120
Study 9689270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8184352 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment including specific manual treatment, such as manipulation and specific mobilization, muscle stretching, auto-traction, and cortisone injections
Number of subjects: 53
Study 8184352 — intervention group
Group type: COMPARATOR
Intervention: Conventional activating treatment
Number of subjects: 53
Study 3812341 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly cooked potato
Number of subjects: 0
Study 3812341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked and cooled potato
Number of subjects: 0
Study 3812341 — intervention group
Group type: EXPERIMENTAL
Intervention: Reheated potato
Number of subjects: 0
Study 3812341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled potato (large lumps vs finely sieved)
Number of subjects: 0
Study 3812341 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with pancreatin
Number of subjects: 0
Study 29458940 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 5% lavender oil for 10 minutes before surgery
Number of subjects: 80
Study 29458940 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 80
Study 28701798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study 28701798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT)
Number of subjects: 60
Study 26152416 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel Spot-on (Profender®) - single application (3 mg/kg emodepside and 12 mg/kg praziquantel)
Number of subjects: 16
Study 26152416 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel Spot-on (Profender®) - two applications (14 days apart)
Number of subjects: 16
Study 26152416 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 16
Study 23826388 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 0
Study 21176949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (375 mg/m² every 8 weeks)
Number of subjects: 1217
Study 21176949 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 1217
Study 21176949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 1217
Study 18279829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2.0 mg/day for 2 weeks
Number of subjects: 40
Study 18279829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 4.0 mg/day
Number of subjects: 40
Study 18279829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2.0 mg/day + medroxyprogesterone acetate
Number of subjects: 40
Study 18279829 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg
Number of subjects: 40
Study 16921034 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 731
Study 16921034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 12456499 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy with factor XIIIA Leu34 allele
Number of subjects: 955
Study 12456499 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy with factor XIIIB Arg95 allele
Number of subjects: 955
Study 12456499 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for both common factor XIII alleles with Arg95 variant and Leu34 variant
Number of subjects: 955
Study 12456499 — intervention group
Group type: EXPERIMENTAL
Intervention: Current estrogen users with at least 2 copies of variant factor XIII alleles
Number of subjects: 955
Study 10326073 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 1309
Study 8592524 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (100 mg per day) and subcutaneous erythropoietin (150 U per kilogram of body weight twice per week)
Number of subjects: 34
Study 8592524 — intervention group
Group type: COMPARATOR
Intervention: Oral iron and placebo
Number of subjects: 34
Study 1955630 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium chromoglycate
Number of subjects: 22
Study 1955630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (4 weeks treatment)
Number of subjects: 22
Study 1955630 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (one dose before exercise)
Number of subjects: 22
Study 1955630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 1955630 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 22
Study 6275778 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 0
Study 6275778 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotics
Number of subjects: 0
Study 29084725 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily clinical measures including strength, palpation, flexibility, and functional tests
Number of subjects: 131
Study 28976863 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based chemotherapy
Number of subjects: 1202
Study 28976863 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-based chemotherapy
Number of subjects: 1202
Study 26250487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling (NC)
Number of subjects: 144
Study 26250487 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study 23829882 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (thrust or nonthrust manipulation) with a standardized exercise program for 2 treatment sessions
Number of subjects: 149
Study 23829882 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (thrust or nonthrust manipulation)
Number of subjects: 149
Study 21930465 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent
Number of subjects: 461
Study 21930465 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 461
Study 18345342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching exercise (2 times daily for 3 weeks) with subtalar joint in supination or pronation
Number of subjects: 33
Study 18345342 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral lower extremity)
Number of subjects: 33
Study 17151364 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106
Study 17151364 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa plus cytarabine
Number of subjects: 1106
Study 12728166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous nasal spray (50 micro g) into each nostril twice daily
Number of subjects: 50
Study 12728166 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 50
Study 10825306 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil-propofol
Number of subjects: 30
Study 10825306 — intervention group
Group type: COMPARATOR
Intervention: alfentanil-propofol
Number of subjects: 30
Study 8864314 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 aerosol 2 mg
Number of subjects: 11
Study 8864314 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 aerosol 4 mg
Number of subjects: 11
Study 8864314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1687425 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 10 mg
Number of subjects: 30
Study 1687425 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg daily
Number of subjects: 30
Study 1687425 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg
Number of subjects: 30
Study 1687425 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 30
Study 1687425 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 1687425 — intervention group
Group type: EXPERIMENTAL
Intervention: not specified
Number of subjects: 30
Study 6135830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml HDCSV intradermally at each of eight sites
Number of subjects: 0
Study 6135830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (im) administration of HDCSV
Number of subjects: 0
Study 6135830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-site id regimen with booster on day 91
Number of subjects: 0
Study 6135830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine given subcutaneously (sc)
Number of subjects: 0
Study 6135830 — intervention group
Group type: COMPARATOR
Intervention: Semple vaccine
Number of subjects: 0
Study 6135830 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rabies-immune globulin (HRIG) at 40 IU per kg
Number of subjects: 0
Study 3755650 — intervention group
Group type: EXPERIMENTAL
Intervention: piperazinedione at a dose of 9 mg/m2 iv every 3 weeks
Number of subjects: 42
Study 3755650 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin
Number of subjects: 42
Study 29510351 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-exposure group (LE)
Number of subjects: 60
Study 29510351 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-exposure group (SE)
Number of subjects: 60
Study 29510351 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 60
Study 27542791 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation balloon-expandable transcatheter heart valve (SAPIEN THV)
Number of subjects: 410
Study 24401928 — intervention group
Group type: EXPERIMENTAL
Intervention: NPLD (50 mg/m² every 3 weeks for six cycles) + trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly) + paclitaxel (80 mg/m² weekly)
Number of subjects: 364
Study 24401928 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel (same doses as above)
Number of subjects: 364
Study 24401928 — intervention group
Group type: EXPERIMENTAL
Intervention: NPLD + trastuzumab + paclitaxel
Number of subjects: 364
Study 24401928 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel
Number of subjects: 364
Study 24401928 — intervention group
Group type: EXPERIMENTAL
Intervention: NPLD + trastuzumab + paclitaxel in ER- and PR-negative tumors
Number of subjects: 364
Study 24401928 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab + paclitaxel in ER- and PR-negative tumors
Number of subjects: 364
Study 22245700 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused intervention
Number of subjects: 0
Study 22245700 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused intervention
Number of subjects: 0
Study 22245700 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study 20060191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 30
Study 20060191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15486001 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 84
Study 15486001 — intervention group
Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 84
Study 14676103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mesna regimen (20% ifosfamide dose) at 0, 4, and 8 h
Number of subjects: 17
Study 14676103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/oral mesna regimen (i.v. mesna at 0 h, oral tablet at 2 and 6 h)
Number of subjects: 17
Study 10560956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA)
Number of subjects: 27
Study 10560956 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age and gender)
Number of subjects: 27
Study 10560956 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 27
Study 10560956 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 7781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation for 15 days
Number of subjects: 30
Study 7781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation for 6 months
Number of subjects: 30
Study 7781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of EFA intake for 3 months
Number of subjects: 30
Study 7781792 — intervention group
Group type: COMPARATOR
Intervention: Control group (advanced colorectal cancer without EFA supplementation)
Number of subjects: 30
Study 7781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) supplementation
Number of subjects: 30
Study 2031511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg q.i.d.)
Number of subjects: 120
Study 2031511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg q.i.d.)
Number of subjects: 120
Study 2031511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets q.i.d.)
Number of subjects: 120
Study 7183131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 40
Study 7183131 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 30923082 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 50
Study 30923082 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study 29677580 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill demonstration video delivered by smartphone
Number of subjects: 87
Study 29677580 — intervention group
Group type: COMPARATOR
Intervention: Regular nursing skills lab demonstration (comparison group)
Number of subjects: 87
Study 27454266 — intervention group
Group type: EXPERIMENTAL
Intervention: TP injections using particulate steroids mixed with a local anesthetic
Number of subjects: 43
Study 27454266 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (control)
Number of subjects: 43
Study 24519657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier decomposition (FD) method for quantifying ventilation
Number of subjects: 20
Study 24519657 — intervention group
Group type: COMPARATOR
Intervention: Previously published methods for quantitative ventilation assessment
Number of subjects: 20
Study 22328340 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 23
Study 22328340 — intervention group
Group type: EXPERIMENTAL
Intervention: No medication (ADHD without MPH)
Number of subjects: 23
Study 22328340 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 20218999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone priming followed by misoprostol
Number of subjects: 388
Study 20218999 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 388
Study 17462517 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16385874 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 antagonists (experimental medications)
Number of subjects: 0
Study 16385874 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide (previously approved medication)
Number of subjects: 0
Study 16385874 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mechanisms of action (attachment inhibitors, CXCR4 inhibitors)
Number of subjects: 0
Study 11285326 — intervention group
Group type: EXPERIMENTAL
Intervention: High genistein intake
Number of subjects: 208
Study 11285326 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein, daidzein, and total isoflavone intake
Number of subjects: 208
Study 9368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 0
Study 9368870 — intervention group
Group type: COMPARATOR
Intervention: No colonoscopy screening (Control)
Number of subjects: 0
Study 8253244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Number of subjects: 113
Study 8253244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 2892336 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995
Number of subjects: 9
Study 2892336 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 plus injection sclerotherapy
Number of subjects: 9
Study 31431112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay with sex-specific thresholds (>16 ng/L women, >34 ng/L men)
Number of subjects: 1941
Study 31431112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I and sex-specific thresholds
Number of subjects: 1941
Study 31431112 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical symptoms
Number of subjects: 1941
Study 31431112 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical features presence
Number of subjects: 1941
Study 28390493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral conjoint therapy (CBCT) for PTSD
Number of subjects: 36
Study 28390493 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 36
Study 25419681 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary feeding for 12 weeks
Number of subjects: 0
Study 25419681 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated until WHZ > -2)
Number of subjects: 0
Study 24308728 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry test and information regarding the test for smoking cessation after 1 year.
Number of subjects: 444